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Hospitalizations for Rotavirus
Gastroenteritis in Gipuzkoa (Basque
Country), Spain
To the Editor: Rotavirus is the main cause of
severe acute gastroenteritis among children both
in developing and in industrialized countries.
The incidence of rotavirus gastroenteritis in
northern Europe is similar to or greater than the
estimated incidence of the disease in the United
States (1-3); however, little is known about the
impact of rotavirus infection on health in
southern Europe.
We examined the incidence of hospitalization
for rotavirus gastroenteritis during 3 years (July
1993-June 1996) in Gipuzkoa (population
400,480, of whom 58,896 are <15 years of age).
The presence of rotavirus antigen was prospec-
tively investigated by enzyme immunoanalysis
(IDEIA Rotavirus, Dako Diagnostics, UK) in
stool samples from all patients <15 years of age in
the study area for whom a microbiologic analysis
was requested for acute gastroenteritis. Chil-
dren hospitalized for rotavirus gastroenteritis
were sought retrospectively through searching
both the computerized records of microbiology
laboratory and hospital medical records for the
diagnoses 558.9 (other gastroenteritis and
presumably noninfectious colitis) and 008.6-
009.3 (enteritis due to specific viruses and
presumably infectious intestinal disorders) (4).
All children in this study lived in the study area,
had been hospitalized for gastroenteritis, and
had one stool sample positive for rotavirus in the
first 5 days of hospitalization without another
gastroenteritis agent detected in the stool.
One hundred fifty-two (82 male and 70
female) of 1,004 children <15 years of age with
rotavirus gastroenterititis had been hospitalized
for rotavirus infection. No deaths were recorded.
Cases usually occurred in epidemic waves, with
the highest incidence in January-March. An
additional 133 children with rotavirus in stools
had been hospitalized but were not included in
this study because they had hospital-acquired
infections (67 cases), were coinfected by another
microorganism (11 cases), came from outside the
geographic study area (19 cases), or had a main
reason for hospitalization other than gastroen-
teritis (36 cases). The mean annual incidence of
hospitalization was 0.86 per 1,000 children
(1 month to 14 years old) and 3.11 per 1,000
children (1 month to 5 years old). The maximum
incidence occurred in 6- to 11-month-old children
(11.81 per 1,000 children). Children were
hospitalized for a mean of 4.8 ± 2.2 days.
Rotavirus gastroenteritis was responsible for 152
(2%) of 7,403 pediatric admissions. For the 1- to
35-month age group, community-acquired
rotavirus gastroenteritis was responsible for 140
(4.6%) of 3,026 admissions.
Although the incidence is based solely on
confirmed cases, the findings closely reflect
disease incidence in our region. The National
System of Health covers 100% of the reference
population, and hospitalization of children in
private institutions is rare. Stool cultures were
taken for most children for gastroenteritis
(94.5%), and the presence of rotavirus was
investigated in every case.
The hospitalization rate observed in this
study was similar to that reported in other
studies from Sweden (2), Denmark (5), and the
United States (6) and lower than that found in
England and Wales (3). In Spain, reporting of
rotavirus infection is not required, is not
included in mortality registers, and is not the
object of specific vigilance by sentinel surveil-
lance systems. Therefore, information about the
incidence and impact of rotavirus infection in
Spain is scarce. However, two reports from Spain
must be highlighted: one is based on a theoretical
prediction using a statistical model (7) and the835 835 835 835 835 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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other is a small clinical and epidemiologic study
of hospitalized children <2 years of age in
Santiago de Compostela (8). Data from both
studies are consistent with our results.
Rotavirus gastroenteritis is a common cause of
hospitalization and produces a heavy load on the
health-care system in our region. After years of
research, vaccines that effectively prevent
rotavirus infections in humans have been
developed (9,10). These data should be consid-
ered in evaluating the potential benefits of
introducing rotavirus vaccine in our region and
monitoring its effectiveness.
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To the Editor:         Mediterranean spotted fever is
endemic in Portugal, where it is a reportable
disease with approximately 1,000 new cases per
year (1). Rickettsia conorii has been thought to
be the only pathogenic rickettsia of the spotted
fever group in Portugal (2), as well as in the
Western Mediterranean area. Another rickettsia
in this group, the Israeli spotted fever rickettsia,
which belongs to the R. conorii complex (3-5),
was isolated in 1974 from ticks and humans;
however, its distribution appeared to be restricted
to Israel (6). We report three cases of rickettsiosis in
Portugal caused by Israeli spotted fever rickettsia.
Case 1. A 71-year-old woman was hospital-
ized with a history of fever (39ºC) for 6 days,
headache, and icterus. The influenzalike syn-
drome was treated with an antipyretic. In the next
4 days, the patient had myalgias, malaise, and
mental confusion. Ten hours after being trans-
ferred to an intensive care unit, she died with
septic shock and multiorgan failure, despite
intravenous administration of doxycycline and
other antibiotics.
Case 2. A 79-year-old woman, who was
previously healthy except for high blood
pressure, was hospitalized with a 4-day history
of gastrointestinal disorders, nausea, and
vomiting, which were attributed to food
poisoning; high fever (40ºC) developed, and 3
days later a cutaneous rash, which spread to the
palms and soles. The diagnosis of Mediterranean
spotted fever was made by indirect immunofluo-
rescent assay against R. conorii (immunoglobu-
lin [Ig] M 1:40; IgG 1:512). The patient was
treated with doxycycline and was discharged
from the hospital 20 days after admission.
Case 3. A 65-year-old woman was hospital-
ized with a 6-day history of fever (39ºC),
headache, vomiting, and epigastric pain, which
had been treated with penicillin. Rash and